Ro 20-1724
(Synonyms: 4-(3-丁氧基-4-甲氧基苯基)咪唑啶-2-酮,4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone) 目录号 : GC13842A selective PDE4 inhibitor
Cas No.:29925-17-5
Sample solution is provided at 25 µL, 10mM.
Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 µM).[1],[2] It weakly inhibits PDE3 with a Ki value greater than 25 µM.1 Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species.[3] It is often used to study cAMP-related functions in vascular cells.[4]
Reference:
[1]. Reeves, M.L., Leigh, B.K., and England, P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochemistry Journal 241, 535-541 (1987).
[2]. Soderling, S.H., Bayuga, S.J., and Beavo, J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proceedings of the National Academy of Sciences of the United States of America 95, 8991-8996 (1998).
[3]. Totani, L., Piccoli, A., Dell'Elba, G., et al. Phosphodiesterases type-4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology 34(8), 1689-1696 (2014).
[4]. Zhai, K., Hubert, F., Nicolas, V., et al. β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells. PLoS One 7(10), 1-13 (2012).
Cas No. | 29925-17-5 | SDF | |
别名 | 4-(3-丁氧基-4-甲氧基苯基)咪唑啶-2-酮,4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | ||
化学名 | (S)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one | ||
Canonical SMILES | O=C(NC1)N[C@H]1CC(C=C2OCCCC)=CC=C2OC | ||
分子式 | C15H22N2O3 | 分子量 | 278.35 |
溶解度 | 25 mg/mL in DMSO, 30 mg/mL in DMF, 25 mg/mL in Ethanol | 储存条件 | Store at- 20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.5926 mL | 17.963 mL | 35.926 mL |
5 mM | 0.7185 mL | 3.5926 mL | 7.1852 mL |
10 mM | 0.3593 mL | 1.7963 mL | 3.5926 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet